



PCT/GB 2004 / 003564



INVESTOR IN PEOPLE

BEST AVAILABLE COPY

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 23 SEP 2004

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed


Dated 31 August 2004

Andrew George



Patents Form 1/77

Patents Act 1977
(Rule 16)



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

NRS/CP6165112

18 AUG 2003

2. Patent application number

(The Patent Office will fill in this part)

0319376.0

3. Full name, address and postcode of the or of each applicant (underline all surnames)

CHROMA THERAPEUTICS LIMITED
92 MILTON PARK
ABINGDON
OXON
OX14 4RY

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

GB

828041 4002

4. Title of the invention

HISTONE MODIFICATION DETECTION

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

MEWBURN ELLIS
York House
23 Kingsway
London WC2B 6HP

Patents ADP number (if you know it)

109006

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if

YES

- a) any applicant named in part 3 is not an Inventor, or
- b) there is an Inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description	37
Claim(s)	8
Abstract	0
Drawing(s)	3

(Handwritten note: 3 + 8 = 11)

10. If you are also filing any of the following, state how many against each item.

Priority documents	0
Translations of priority documents	0
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	0
Request for preliminary examination and search (Patents Form 9/77)	0
Request for substantive examination (Patents Form 10/77)	0
Any other documents (please specify)	0

11. I/We request the grant of a patent on the basis of this application.

Signature
Mervyn Ellis

Date
15 AUGUST 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

020 7240 4405

NICHOLAS R SUTCLIFFE

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

Histone Modification Detection

This invention relates to the diagnosis of disease conditions, such as cancer and autoimmune disease, by the 5 analysis of cell-free nucleosomes in samples from individuals, in particular the analysis of cell-free nucleosomes containing histone modifications.

In eukaryotes, DNA is complexed with proteins to form 10 nucleosomes, the basic sub-unit of chromatin. Nucleosomes consist of approximately 150 DNA base pairs wrapped around a histone core, which is a protein complex involving the four histones H4, H3, H2B and H2A. The amino-terminal tails of these proteins are among the most 15 evolutionary conserved proteins known. These tails are post-translationally modified by the addition of a range of chemical groups including methyl, acetyl and phosphoryl. These chemical modifications, or marks, play a key role in determining chromatin structure and hence 20 access to the cells genomic DNA (Wu J and Grunstein M (2000) Trends Biochem. Sci. 25, 619-623; Berger SL (2001) Oncogene 20, 3007-3013). It has also been shown that the marks are involved in the control mechanism for a wide 25 range of cellular processes. For example, in general, deacetylation of marks and certain methylation marks are associated with gene silencing (Hu JF and Hoffman AR (2001) Methods Mol Biol. 181, 285-296; Rice JC and Allis CD (2001) Curr Opin Cell Biol 13, 263-273; Carrozza MJ et al (2003) Trends Genet 19, 321-329; Nepheu KP and Huang 30 TH (2003) Cancer Lett 190, 125-133) and phosphoryl marks with apoptosis (Enomoto R et al (2001) Mol Cell Biol Res Commun 4, 276-281; Ajiro K (2000) J Biol Chem 275, 439-443; Talasz H, et al (2002) Cell Death Differ 9, 27-39; Rogakou EP et al (2000) J Biol Chem 275, 9390-9395) and

mitosis (Crosio et al (2002) Mol Cell Biol 22 874-885; Goto et al (2002) Genes Cells 7, 11-17; Hans and Dimitrov (2001) Oncogene 20, 3021-3027; Preuss et al (2003) Nucl Acids Res 31, 878-885). Nucleosomes marked in a specific 5 manner can be isolated from cells by using specific antibodies, and the DNA component analysed (for example, Clayton et al (2000) EMBO J 19, 3714-3726; Li et al (2001) Mol Cell Biol 21, 8213-8224; Osano and Ono (2003) Eur J Biochem 270, 2532-2539; Kondo and Issa (2003) J 10 Biol Chem In press).

Patients suffering from conditions, such as cancer and autoimmune disease, have nucleosomes circulating in the blood resulting from increased apoptosis (Holdenrieder et 15 al (2001) Int J Cancer 95, 114-120; Trejo-Becerril et al (2003) Int J Cancer 104, 663-668; Kuroi et al 1999 Breast Cancer 6, 361-364; Kuroi et al (2001) Int J Oncology 19, 143-148; Amoura et al (1997) Arth Rheum 40, 2217-2225; Williams et al (2001) J Rheumatol 28, 81-94).

20 Measurement of the levels of cell-free nucleosomes has been proposed as a means of diagnosing diseases associated with apoptosis (Holdenrieder et al (1999) Anticancer Res, 19, 2721-2724). However, the presence of cell-free nucleosomes with specific marks was not 25 assessed.

The present invention relates to methods for detecting 30 nucleosomes containing modified histones in samples from patients, in particular methods that involve antibody-antigen interactions.

Various aspects of the invention relate to the use of antibodies which specifically bind to modified histones

to detect nucleosomes in samples which comprise modified histones.

One aspect of the invention provides a method of
5 assessing a disease condition in an individual
comprising;

concentrating nucleosomes from a biological fluid
obtained from the individual; and,

10 contacting said concentrated nucleosomes with an
antibody which binds specifically with a modified histone
protein,

wherein binding of said antibody to one or more of
said nucleosomes is indicative of a disease condition in
the individual.

15 A disease condition in the individual may be assessed by
determining one or more of: the presence of one or more
histone modifications in the sample, an increase in the
number of cell-free nucleosomes containing modified
20 histones in the sample relative to normal levels, an
alteration in the ratio of one or more particular histone
modifications relative to another histone modifications
in the sample and a threshold number of nucleosomes in
the sample which comprise a histone modification.

25 After the biological fluid sample has been contacted with
the antibody under conditions suitable to allow specific
binding of the antibody to its target antigen,
nucleosomes comprising the modified histone may be
30 identified and, optionally, isolated using standard
techniques.

A biological fluid suitable for use in accordance with
the present methods may include sera, plasma, lymph,

blood, blood fractions, urine, synovial fluid, spinal fluid, saliva, and mucous. Blood, serum or plasma are preferred.

5 Nucleosomes may be concentrated from the sample of biological fluid by any convenient concentration method, including, for example:

- centrifugal filtration such as centrifugal filtration units with an appropriate molecular weight cut-off membrane e.g. Millipore's Centricon® or Amicon® units,
- acid precipitation (Yoshida, M et al, (1990), J Biol Chem **265**, 17174-17179).
- immunoprecipitation using conventional methods, for example, by incubating the sample with an anti-nucleosome antibody or a histone mark-specific antibody, and then immunopurifying the antibody/antigen complex using a spin column packed with an immunoaffinity matrix. The captured nucleosomes would then be eluted and analysed.
- Separation based on charge, for example, binding to polyK coated solid supports (Williams RC et al, (2001) J Rheumatol **28**, 81-94).
- Separation based on biotinylation. Histones can be biotinylated by biotinidase (Hymes J et al (1995), Biochem Mol Med **56**, 76-83; Stanley JS et al, (2001) Eur J Biochem **268**, 5424-5429.

30 In some embodiments, nucleosomes may be concentrated by a method other than collection on a poly K or streptavidin-coated support.

A histone mark may be a post-translational chemical change to one or more histone amino acid residues, for example addition/removal of a chemical group or isomerisation of an amino acid residue.

5

An antibody specific for a modified histone is specific for a unique epitope formed by post-translational modification of a core histone, for example histone H2A, H2B, H3, H4 (Luger, K. et al (1997) *Nature* **389**, 251-260)

10 or a modification or variant thereof (see for example (Ausio J (2001) *Biochem Cell Bio* **79**, 693). Known sequences of histones are described in the NHGRI/NCBI histone sequence database which is accessible on-line.

15 A modification may be in the central region of a histone or in the flexible N-terminal or C-terminal tail.

Post-translational modification may include acetylation, methylation, which may be mono-, di- or tri-methylation, 20 phosphorylation, ribosylation, citrullination, ubiquitination, hydroxylation, glycosylation, nitrosylation, glutamination and/or isomerisation (Ausio J (2001) *Biochem Cell Bio* **79**, 693).

25 A lysine residue which is methylated may be mono-, di- or tri-methylated. An arginine residue which is methylated may be symmetrically or asymmetrically dimethylated, or monomethylated.

30 An histone amino acid residue having a modification may be any Ser, Lys, Arg, His, Glu, Pro or Thr residue within the histone amino acid sequence.

For example, a lysine residue within the core histone sequence may be mono-, di- or tri-methylated, acetylated or ubiquitinated, an arginine residue within the core histone sequence may be monomethylated, symmetrically or 5 asymmetrically dimethylated or converted to citrulline, a serine or threonine residue within the core histone sequence may be phosphorylated and/or a proline residue within the core sequence may be isomerised.

10 The notation used to describe a particular histone modification indicates which histone has been modified, the particular amino acid(s) that have been modified and the type of modification that has occurred. For example H3 Lys 9(Me) denotes the methylation of histone H3 at 15 lysine 9.

Examples of modifications include modifications shown in table 1:

20 A histone mark which produces a cellular effect may consist of one modification to a histone or may consist of two or more histone modifications. In other words, a single mark, which may for example be associated with silencing or activation, may consist of a combination of 25 separate modifications to different residues within a histone sequence.

For example, a modified histone may comprise a mark which is associated with gene silencing, such as H3 Lys 9(Me) 30 H3 Lys 27(Me), H3 Lys 36(Me), H3 Lys 79(Me) and H4 Lys 20(Me) or a mark which is associated with gene activation, such as H3 Lys 4(Me) H3 Lys 9(Ac), H3 Lys 14(Ac) and H3 Lys 23(Ac)

Antibodies which are specific for histone marks that are associated with active gene sequences (euchromatin) or inactive gene sequences (heterochromatin) may be used, for example, to detect inappropriate gene expression 5 which is indicative of a disease state. Screening the population of cell-free nucleosomes present in a sample from an individual may reveal the inactivation of a tumour suppression gene or alternatively, the activation of an oncogene.

10

A 'modified nucleosome' is a nucleosome which comprises a histone comprising one or more modifications as described above.

15 An antibody which specifically binds to an antigen such as a modified histone or nucleosome may not show any significant binding to molecules other than the antigen. An antibody may specifically bind to a particular epitope which is carried by a number of antigens, in which case 20 the antibody will be able to bind to the various antigens carrying the epitope.

In some embodiments, a disease condition may be assessed by determining the presence of two or more histone 25 modifications in cell-free nucleosomes in the sample. In particular, the presence of a histone mark consisting of more than one modification may be determined by determining the presence of the two or more separate modifications. Two or more histone modifications in a 30 sample may be characterised by contacting the sample with an antibody that specifically binds to two or more histone modifications or alternatively, contacting the sample with two or more antibodies, each antibody specifically binding to a different histone modification.

Another aspect of the invention comprises a method of assessing histone modification in cell-free nucleosomes in a biological fluid sample comprising;

5 contacting a biological fluid sample with an antibody which binds specifically to a histone comprising a modification; and,

 determining the binding of said antibody to nucleosomes in said sample,

10 the binding of said antibody being indicative of the presence of modified histone in nucleosomes in the blood of said individual.

An antibody may specifically bind to a histone modification described above, for example a modification shown in Table 1, or a combination of such modifications.

In some preferred embodiments, an antibody may bind specifically to a histone comprising a modification shown 20 in Table 2 or a combination of such modifications.

In some embodiments, the biological fluid sample may be contacted with a further antibody which binds specifically to histone comprising a different 25 modification from the first antibody. A range of antibodies may be employed to detect the presence of a range of histone modifications.

Cell-free nucleosomes in fluid samples from patients may 30 be used to assess disease conditions associated with cell death, in particular cancer and/or autoimmune disease. For example, the presence of cancer cells in an individual may generate a higher level of cell free nucleosomes in the blood as a result of the increased

apoptosis of the cancer cells. An antibody directed against marks associated with apoptosis, such as H2B Ser 14(P), may be used to selectively isolate nucleosomes that have been released from apoptotic neoplastic cells.

5

Another aspect of the invention provides a method of assessing a disease condition in an individual comprising;

10 contacting biological fluid sample obtained from an individual with an antibody which binds specifically to a modified histone,

determining the binding of said antibody to nucleosomes in said sample,

15 the binding of said antibody to nucleosomes in said sample being indicative that said individual has a disease condition.

A modified histone may, for example, have a modification selected from the group consisting of H2B Ser 14 (Phos), 20 H3 lys 9(Me), H3 lys 27(Me) and H3 Ser 10 (Phos). In some embodiments, the modified histone is not H2B Ser 14(Phos).

25 Diseases associated with modified, cell-free nucleosomes include, but are not limited to, pre-malignant and malignant neoplasms and tumours, (e.g., histocytoma, glioma, astrocytoma, osteoma), cancers (e.g., lung cancer, small cell lung cancer, gastrointestinal cancer, bowel cancer, colon cancer, breast carcinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreas cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, melanoma), leukemias, autoimmune diseases (e.g. systemic lupus erythematosus) and proliferative disorders (e.g.

psoriasis, bone diseases, fibroproliferative disorders of connective tissue, cataracts and atherosclerosis).

5 A pre-malignant or malignant condition may occur in any cell-type, including but not limited to, lung, colon, breast, ovarian, prostate, liver, pancreas, brain, and skin.

10 An antibody that specifically binds to a modified histone may be generated using techniques which are conventional in the art. Methods of producing antibodies include immunising a mammal (e.g. mouse, rat, rabbit, horse, goat, sheep or monkey) with a modified histone or a peptide fragment of the histone which comprises the 15 modification or mark. Peptide fragments with particular modifications can be designed from known histone sequences and produced by routine synthesis methods. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and 20 screened, preferably using binding of antibody to antigen of interest. For instance, Western blotting techniques or immunoprecipitation may be used (Armitage et al., (1992) Nature 357, 80-82).

25 As an alternative or supplement to immunising a mammal with a peptide, an antibody specific for a protein may be obtained from a recombinantly produced library of expressed immunoglobulin variable domains, e.g. using lambda bacteriophage or filamentous bacteriophage which 30 display functional immunoglobulin binding domains on their surfaces; for instance see WO92/01047. The library may be naive, that is constructed from sequences obtained from an organism which has not been immunised with any of the proteins (or fragments), or may be one constructed

using sequences obtained from an organism which has been exposed to the antigen of interest.

5 Antibodies suitable for use in accordance with the present methods are also available from commercial suppliers.

10 The binding of an antibody may be determined by any appropriate means. Tagging with individual reporter molecules is one possibility. The reporter molecules may directly or indirectly generate detectable, and preferably measurable, signals. The linkage of reporter molecules may be directly or indirectly, covalently, e.g. via a peptide bond or non-covalently. Linkage via a 15 peptide bond may be as a result of recombinant expression of a gene fusion encoding antibody and reporter molecule.

Radioimmunoassay (RIA) is another possibility.

20 Radioactive labelled antigen is mixed with unlabelled antigen (the test sample) and allowed to bind to the antibody. Bound antigen is physically separated from unbound antigen and the amount of radioactive antigen bound to the antibody determined. The more antigen there is in the test sample, the less radioactive antigen will 25 bind to the antibody. A competitive binding assay may also be used with non-radioactive antigen, using antigen or an analogue linked to a reporter molecule. The reporter molecule may be a fluorochrome, phosphor or laser dye with spectrally isolated absorption or emission 30 characteristics. Suitable fluorochromes include fluorescein, rhodamine, phycoerythrin and Texas Red. Suitable chromogenic dyes include diaminobenzidine.

Other reporters include macromolecular colloidal particles or particulate material such as latex beads that are coloured, magnetic or paramagnetic, and biologically or chemically active agents that can

5 directly or indirectly cause detectable signals to be visually observed, electronically detected or otherwise recorded. These molecules may be enzymes which catalyse reactions that develop or change colour or cause changes in electrical properties, for example. They may be

10 excitable, such that electronic transitions between energy states result in characteristic spectral absorptions or emissions. They may include chemical entities used in conjunction with biosensors.

Biotin/avidin or biotin/streptavidin and alkaline

15 phosphatase detection systems may be employed. The mode of determining binding is not a feature of the present invention and those skilled in the art are able to choose a suitable method according to their preference and general knowledge.

20 The signals generated by individual antibody-reporter conjugates may be used to derive quantifiable absolute or relative data of the relevant antibody binding in samples (normal and test).

25 Methods of the invention may be carried out in any convenient format. Immunological assays are well-known in the art and many suitable formats are available, for example ELISA, Western blotting, or Biacore® ,(Biacore, 30 Upsala, Sweden). In some preferred embodiments, a sandwich assay format may be employed. A sandwich assay employs a capture antibody and a detection antibody to detect the presence of antigen in a sample. The capture antibody may, for example, bind specifically to a

nucleosome and the detection antibody to a histone with a particular modification, or vice versa.

Another aspect of the invention provides a method of 5 assessing histone modification in cell-free nucleosomes in a biological fluid sample from an individual comprising;

contacting a biological fluid sample from said individual with a first antibody; and,

10 determining binding of said first antibody to a nucleosome comprising a histone modification using a second antibody,

wherein one of said first or second antibodies binds to a nucleosome and the other of said first or second 15 antibodies binds specifically to a modified histone.

In some embodiments, the first antibody binds to nucleosomes and the second antibody binds specifically to the modified histone. A method of assessing histone 20 modification in nucleosomes in a biological fluid sample from an individual may thus comprise;

contacting a biological fluid sample from said individual with a first antibody which binds to nucleosomes; and,

25 determining the presence of a modified histone in a nucleosome bound by said first antibody using a second antibody which binds specifically to a modified histone.

Antibodies which bind specifically to modified histones 30 are described in more detail above. An antibody which binds to a nucleosome may bind to any epitope commonly found on any unmodified component of the nucleosomes, including histone and non-sequence specific DNA epitopes. In some embodiments, an antibody may bind to both the

histone and DNA components of the nucleosome. An antibody may bind specifically to one or more nucleosome components.

- 5 Suitable anti-nucleosome antibodies include the antibody known as clone 11E6 (available from BD PharMingen) which interacts with the (H2A-H2B)-DNA sub-nucleosomal complex (Jovelin F et al (1998) Eur J Immunol 28, 3411).
- 10 In other embodiments, the second antibody binds to nucleosomes and the first antibody binds specifically to the modified histone. A method of assessing histone modification in nucleosomes in a biological fluid sample from an individual may thus comprise;
 - 15 contacting a biological fluid sample from said individual with a first antibody which binds specifically to a modified histone,
 - 20 determining the binding of said first antibody to a nucleosome comprising a modified histone using a second antibody which binds to a nucleosome.

One of said first and second antibodies may be immobilised and the binding of the other antibody may be detected. Preferably, the first antibody is immobilised.

- 25 An antibody may be immobilised, for example, by attachment to an insoluble support. The support may be in particulate or solid form and may include a plate, a test tube, beads, a ball, a filter or a membrane. An antibody may, for example, be fixed to an insoluble support that is suitable for use in affinity chromatography. Methods for fixing antibodies to insoluble supports are known to those skilled in the art.
- 30 An antibody may be immobilised, for example, to isolate cell-free nucleosomes from the biological fluid sample.

The non-immobilised antibody may comprise a detectable label as described above. For example, the antibody may be labeled with a fluorophore such as FITC or rhodamine, 5 a radioisotope, or a non-isotopic labeling reagent such as biotin or digoxigenin; antibodies containing biotin may be detected using "detection reagents" such as avidin conjugated to any desirable label such as a fluorochrome.

10 In some embodiments, the non-immobilised antibody may be detected using a third antibody which binds to said non-immobilised antibody. A suitable third antibody is labelled and binds specifically to the first or second antibody. The third antibody may comprise a detectable 15 label.

In some embodiments, a blocking reagent may be used to block or absorb interfering endogenous components, such as antibodies or proteins. For example, samples may be 20 depleted of endogenous antibodies by, for example, application to a spin column packed with an immunoaffinity matrix to remove immunoglobulin. Alternatively, the potential interference by heterophilic antibodies could be minimised by the use of a blocking 25 reagents. Suitable blocking reagents are available commercially, for example, HBR from Scantibodies Ltd (Santee, Calif, US)). Excess albumin in samples may conveniently be depleted by using an albumin affinity spin column (Montage™ Albumin Deplete kit, Millipore). 30

Antibodies specific for modified histones may be used to detect any abnormal modifications that would indicate a disease state. Alternatively, the nucleic acid sequences associated with modified nucleosomes may be analyzed

using standard techniques to assess a disease condition or susceptibility to a disease condition.

Methods as described herein may be used to isolate and/or 5 identify nucleic acid sequences associated with a particular mark. These nucleic acid sequences may be associated with a disease condition. Identifying the DNA associated with modified nucleosomes may also be useful in monitoring the progress of a therapeutic treatment, 10 for example, monitoring positive and/or adverse effects resulting from treatment.

Methods of the invention may comprise isolating a nucleosome comprising a modified histone. Nucleosomes comprising modified histones may be isolated by 15 immunoprecipitation using a modified histone-specific antibody or a nucleosome specific antibody as described herein. Alternatively, nucleosomes may be isolated by binding to an immobilised antibody, as described above.

20 Once the nucleosomes have been isolated from the sample, the DNA associated with the nucleosomes can be recovered using standard techniques. For example, DNA may be immobilised onto filters, column matrices, or magnetic 25 beads. Numerous commercial kits, such as the Qiagen QIAamp kit (Qiagen, Crawley, UK) may be used. Briefly, the sample may be placed in a microcentrifuge tube and combined with Proteinase K, mixed, and allowed to incubate to lyse the cells. Ethanol is then added and the 30 lysate is transferred to a QIAamp spin column from which DNA is eluted after several washings. Optionally, the isolated DNA may be amplified through PCR or other amplification techniques. The sequence of the nucleosome-associated DNA may be obtained, for example to

identify the polypeptide encoded by the DNA. Nucleosome associated DNA may be associated with a particular histone mark or modification. For example, depending on the binding specificity of the antibody used to initially 5 isolate the nucleosomes from the sample, genes may be identified that are associated with activation or silencing marks.

Any of analytical procedures known to those skilled in 10 the art may be used to identify the DNA sequences associated with isolated nucleosomes. DNA sequences may, for example, be identified by direct microsequencing of the purified DNA. Alternatively, the purified DNA may be first amplified using PCR technology or other amplifying 15 technique before further analysis of the DNA.

In some embodiments, the DNA associated with the isolated nucleosomes may be identified by contacting the purified DNA with known nucleic acid sequences under conditions 20 suitable for hybridisation of complementary sequences, wherein hybridisation of the purified DNA to its complement identifies the purified DNA sequence; and determining hybridisation. For example, Southern Blot analysis may be conducted in which either the known DNA 25 sequences or the purified DNA serves as the labelled probe, and the unlabeled sequences are immobilized on a solid surface. Formation of nucleic acid duplexes is then detected. The nucleosome-associated DNA can then be identified from the sequence(s) to which it hybridises.

30 Nucleic acid probes can be labelled with a detectable marker using standard techniques known to those skilled in the art. For example the nucleic acid probes can be labelled with a fluorophore, a radioisotope, or a

non-isotopic labelling reagent such as biotin or digoxigenin.

Known nucleic acid sequences, for example, sequences from 5 various genes of interest, may be immobilized on a solid surface, as described above. Preferably, the sequences are immobilized in the form of a microarray, in which each known sequence is assigned a position on a solid surface. Preferably, the microarray comprises a 10 plurality of DNA molecules, each having a different known sequence. The purified nucleosome DNA may be labelled and then placed in contact with a microarray of known sequences under conditions suitable for the hybridisation of complementary sequences. After a predetermined length 15 of time the unbound and non-specifically bound material may be washed from the microarray and the array I screened for detectable signals. A signal generated at a specific position on the solid surface by hybridisation of a purified nucleosome DNA sequence to its complement, 20 identifies the purified nucleosome DNA sequence.

Microarrays allow miniaturisation of assays, e.g. making use of binding agents (such as nucleic acid sequences) immobilised in small, discrete locations (microspots) 25 and/or as arrays on solid supports or on diagnostic chips. These approaches can be particularly valuable as they can provide great sensitivity (particularly through the use of fluorescent labelled reagents), require only very small amounts of biological sample from individuals 30 being tested and allow a variety of separate assays to be carried out simultaneously. This latter advantage can be useful as it provides an assay for a number of different sequences to be carried out using a single sample. Examples of techniques enabling this miniaturised

technology are provided in WO84/01031, WO88/1058, WO89/01157, WO93/8472, WO95/18376/ WO95/18377, WO95/24649 and EP-A-0373203, the subject matter of which are herein incorporated by reference.

5

The principles of microarray hybridisation are described in Yershov, G. et al (1996) Proc Natl Acad Sci USA 93 4913-4918, Cheung V. G. et al (1999) Nature Genetics 21 15-19, and Schena, M. (1999) DNA Microarrays "a practical 10 approach", ISBN, 0-19-963777-6, Oxford press, editor B. D. Hames. In brief, the DNA microarray may be generated using oligonucleotides that have been selected to hybridise with the specific target polymorphism. These oligonucleotides may be applied by a robot onto a 15 predetermined location of a glass slide, e.g. at predetermined X, Y cartesian coordinates, and immobilised. The sample RNA or DNA (e.g. fluorescently labelled RNA or DNA) is introduced on to the DNA microarray and a hybridisation reaction conducted so that 20 sample RNA or DNA binds to complementary sequences of oligonucleotides in a sequence-specific manner, and allow unbound material to be washed away. Sequences can thus be identified by their ability to bind to complementary oligonucleotides on the array and produce a signal. The 25 absence of a fluorescent signal for a specific oligonucleotide probe indicates that the sequence of the sample DNA or RNA is not present on the micoarray. Of course, the method is not limited to the use of fluorescence labelling but may use other suitable labels 30 known in the art. Fluorescence at each coordinate can be read using a suitable automated detector, in order to correlate each fluorescence signal with a particular oligonucleotide.

Hybridisation of nucleosome associated DNA from said individual may be compared with the hybridisation of nucleosome associated DNA from other individuals. For example, hybridisation patterns from a patient with a proliferative disorder may be compared with patterns from a healthy individual to identify genes whose chromatin is differentially marked (for example, activated or inactivated) in the proliferative disorder. For example, a tumour suppressor gene may be associated with a silencing mark or an oncogene with an activation mark in a cancer condition.

An aspect of the invention provides a method of identifying a tumour suppressor gene comprising;

15. contacting biological fluid sample obtained from an individual having a cancer condition with an antibody which binds specifically to a histone having a modification associated with silencing,

isолating nucleosomes bound to said antibody,

20. sequencing DNA associated with said bound nucleosomes;

and,

identifying said DNA as a tumor suppressor gene.

A method may comprise comparing said DNA with DNA associated with said bound nucleosomes in sample from a healthy individual (i.e. an individual not having a cancer condition). A DNA sequence which is associated with a silencing mark in the cancer sample but not the non-cancer sample is a candidate tumour suppressor.

30

In some embodiments, a modification associated with silencing may exclude Lys 9 methylation of histone H3.

A method may include concentrating the nucleosomes in the sample by a method other than collection on a poly K or streptavidin-coated support, prior to contacting with the antibody.

5

A method of identifying a tumour suppressor gene may include contacting the nucleosomes with a first antibody which binds specifically to a histone having a modification associated with silencing and a second antibody which binds to nucleosomes, for example in a sandwich assay format.

10

An aspect of the invention provides a method of identifying an oncogene comprising;

15

contacting biological fluid sample obtained from an individual suffering from a cancer condition with an antibody which binds specifically to a histone having a modification associated with activation,

isolating nucleosomes bound to said antibody,

20

sequencing DNA associated with said bound nucleosomes, and;

identifying said DNA as an oncogene.

25

Modifications associated with gene activation are described in more detail above. In some embodiments, a modification associated with activation may exclude H3 Lys 4 (Me), H3 Lys 9 (Ac) and/or H4 Lys 5 (Ac).

30

A method may comprise comparing said DNA with DNA associated with said bound nucleosomes in sample from a healthy individual (i.e. an individual not having a cancer condition). A DNA sequence which is associated with an activation mark in the cancer sample but not the non-cancer sample is a candidate oncogene.

A method may include concentrating the nucleosomes in the sample by a method other than collection on a polyK or strepavidin-coated support, prior to contacting with the 5 antibody.

A method of identifying an oncogene may include contacting the nucleosomes with a first antibody which binds specifically to a histone having a modification 10 associated with silencing and a second antibody which binds to nucleosomes, for example in a sandwich assay format.

Methods described herein may be useful in detecting 15 chromatin alterations which are associated with a disease condition. Cell-free nucleosomes may be isolated from samples from healthy individuals and from individuals having a disease condition, using a modified histone specific antibody and optionally a nucleosome specific 20 antibody, to generate a first and second pool of nucleosomes, respectively. Preferably, methods of detecting chromatin alterations associated with disease comprise contacting the nucleosomes with a first antibody which binds specifically to a histone having a 25 modification and a second antibody which specifically binds to nucleosomes, for example in a sandwich assay format.

After isolation, the nucleic acid associated with the 30 isolated nucleosomes may be isolated and/or purified from the first and second pools of nucleosomes to generate a first and second pool of purified nucleic acid. The purified nucleic acid in each pool is then analyzed, using standard molecular techniques such as DNA

sequencing, nucleic acid hybridization analysis (including Southern blot analysis), PCR amplification or differential screening, to identify differences between the two pools of nucleic acid sequences. Those nucleic acid sequences that are present in only one of the two pools represent nucleic acid sequences that are potentially related to the disease condition.

For example, the pools of nucleic acid sequences may be 10 separately contacted with identical sets of DNA microarrays under conditions that allow for hybridization between complementary sequences. The microarrays may, for example, contain a subset of sequences that are associated with particular diseases (such as various 15 known oncogene and tumor suppressor genes) or may contain the entire set of expressed sequences for one or more particular cell types and developmental stages.

Hybridisation between a sequence in the pool of nucleosome associated nucleic acid and a nucleic acid 20 sequence immobilised within the microarray produces a detectable signal, which allows the nucleosome associated nucleic acid to be identified. Suitable microarrays can be prepared using techniques known to those skilled in the art.

25 In some embodiments, the pools of nucleosome-associated nucleic acid may be amplified by PCR and/or labelled prior to contacting them with the microarray. Washing of the microarray removes non-bound and non-specifically 30 bound material and allows detection of the labelled sequences that have specifically hybridised to sequences present on the microarray, thus identifying of the labelled sequences. Comparison of the hybridisation patterns obtained with the first and second pools of

nucleosome-associated nucleic acid allows the identification of chromatin alterations that are potentially associated with a disease condition.

5 Pools of nucleosomes may be compared using a gene chip, DNA microarray, or a proteomics chip using standard techniques known to those skilled in the art (For example, WO 01/16860, WO 01/16860, WO 01/05935, WO 00/79326, WO 00/73504, WO 00/71746 and WO 00/53811).

10 Methods as described herein also allow the identification of genomic DNA which is associated with particular markers. DNA which is associated with a nucleosome having a particular histone modification may, for example, be immobilized on a solid surface or "chip".

15 This DNA may, for example, represent all the nucleic acid sequences of a given cell that is competent for transcription or not competent for transcription, depending on the histone modification (for example, active: H3 lys 4 (Me), inactive: H3 lys 9 (Me)).

20

Other aspects of the invention relate to the identification and monitoring of patients having disease conditions which are associated with the aberrant marking of histones.

25 A method of identifying a patient as a responsive to histone modification modulation therapy may comprise; determining the level of histone modification in cell-free nucleosomes within a sample obtained from the patient, relative to a sample obtained from a healthy individual,

30 a change, for example an increase or decrease, in the level of modification being indicative that the

patient is responsive to histone modification modulation therapy.

5 Methods of the invention may also be used to monitor the effect of histone modification modulation therapy.

Histone modification modulation therapy may include, for example, inhibition of histone modifying or de-modifying enzymes, such as histone methyl transferases, acetylases and deacetylases.

10

A method of monitoring the effect of histone modification modulation therapy in a patient may comprise;

15 contacting samples obtained from the patient at first and second time points in said therapy with an antibody which specifically binds to a histone having a modification; and

determining binding of said antibody to said samples;

20 a change, for example an increase or decrease, in the binding of said antibody to the sample obtained at the second time point relative to the first being indicative of the effect of said therapy.

25 A patient may be suffering from a cancer or autoimmune condition, as described above.

For example, tumour cells may over-express enzymes that remove acetyl marks, leading to reduced expression of tumour suppressor genes- (Johnstone RW (2002) Nature

30 Reviews Drug Discovery, 1, 287). Patients identified using the present methods as having reduced histone acetylation may be treated with an agent which inhibits histone deacetylating enzymes. This increases histone acetylation, thereby increasing expression of tumor

suppressor genes. The effect of therapy may be monitored by determining an increase in the level or amount of acetylation marks.

5 Aurora kinase B, which phosphorylates H3 Ser 10, is over-expressed in many cancer conditions. Aurora kinase B inhibitors have been shown to have an anti-proliferative effect which is associated with inhibition of this histone marking step (Ditchfield C (2003) J. Cell Biol. 161, 267). Patients with increased phosphorylation at H3 Ser 10 may be identified using methods of the invention and the effects of treatment with an aurora kinase inhibitor monitored.

10 15 Other aspects of the invention relate to the analysis of the DNA associated with specifically marked nucleosomes in order to identify the appropriate treatment regimes. For example, such analysis may indicate the propensity of 20 a tumour to metastasise, the hormone dependence of a tumour, or the activation in a tumour of certain resistance genes and pathways, for example, glutathione S-transferase-pi (Townsend D and Tew K (2003) Am J Pharmacogenomics 3, 157-172), multidrug resistance 25 associated protein, p-glycoprotein (Mattern J (2003) Anticancer Res 23, 1769-1772) and glyoxalase-I (Tsuruo T (2003) Cancer Sci 94, 15-21). The effect of treatment regimes could be monitored, for example, by observing changes in gene silencing/activation marks associated 30 with these genes.

A method of assessing a patient for a therapeutic treatment may comprise;

determining the presence of one or more genes which confer resistance to said treatment in a cell-free nucleosome in a sample obtained from the patient, as described above,

5 wherein said nucleosome comprises or contains a histone modification associated with activation or silencing.

10 Histone modifications associated with activation or silencing are described in more detail above.

15 Various further aspects and embodiments of the present invention will be apparent to those skilled in the art in view of the present disclosure. All documents referenced in this specification are incorporated herein by reference.

20 All combinations and sub-combinations of the features described above, whether or not specifically described or exemplified, are encompassed by the invention.

25 Certain aspects and embodiments of the invention will now be illustrated by way of example and with reference to the figures and table described below.

Figure 1 shows the efficient recovery and detection of marked (dimethylated Lys 4 of histone H3) chicken nucleosomes spiked into human blood.

30 Figure 2 shows the analysis of a plasma sample from a patient with ovarian cancer using an antibody to dimethylated Lys 4 of histone H3.

Figure 3 shows the analysis of a plasma sample from a patient with ovarian cancer using an antibody to acetylated Lys 9 of histone H3.

5 Table 1 shows a list of known histone marks. In the table, Me = mono, di or trimethyl, Ac = Acetyl, Phos = Phosphorylation, Ubiq = Ubiquitinated (For Arg, Me can mean mono or dimethylated, where dimethylation can be symmetrical or asymmetrical).

10 Table 2 shows examples of preferred marks according to the invention. As for table 1, Me = mono, di or trimethyl, Ac = Acetyl, Phos = Phosphorylation, Ubiq = Ubiquitinated (For Arg, Me can mean mono or dimethylated, where dimethylation can be symmetrical or asymmetrical).

15 Table 3 shows examples of peptides which may be used to generate modified histone specific antibodies.

20 Examples

Materials and Methods

Collection and preparation of healthy volunteer blood samples

20ml of blood were withdrawn by venepuncture into 25 vacutainer tubes containing sodium citrate, which were then kept on ice. Purified chicken nucleosomes were spiked into the blood (or buffer). Platelet rich plasma (PRP) was prepared within 4 hours of blood collection by centrifugation at 300g for 20 minutes. An appropriate 30 volume of 20x inhibitor cocktail was added directly to the resultant PRP (resulting in supramaximal concentrations of okadaic acid, cypermethrin, staurosporine, trichostatin A, AEBSF, aprotinin, E-64, EDTA and leupeptin). Platelet poor plasma (PPP) was

generated by centrifugation of the PRP on a Percoll underlay at 2000g for a further 20 minutes.

Collection of cancer patients' blood samples and
preparation of plasma

20ml of blood were withdrawn by venepuncture into vacutainer tubes containing sodium citrate, which were then kept on ice. Platelet rich plasma (PRP) was prepared within 4 hours of blood collection by centrifugation at 10. 300g for 20 minutes. An appropriate volume of 20x inhibitor cocktail was added directly to the resultant PRP (resulting in supramaximal concentrations of okadaic acid, cypermethrin, staurosporine, trichostatin A, AEBSF, aprotinin, E-64, EDTA and leupeptin). Platelet poor 15 plasma (PPP) was generated by centrifugation of the PRP on a Percoll underlay at 2000g for a further 20 minutes.

Detection by ELISA of covalent modifications on nucleosomes from human blood samples

An indirect sandwich ELISA was used to detect covalent 20 modifications of histones of nucleosomes from human blood samples.

An anti-nucleosome antibody, obtained from BD PharMingen, was attached to a solid phase and used to capture native 25 nucleosomes present in patient plasma samples or chicken nucleosomes spiked into buffer or normal blood.

Detection antibodies then target various specific histone marks. Such anti-modified histone antibodies are commercially available from a number of sources, notably 30 Upstate Ltd (Charlottesville US) and Abcam Ltd (Cambridge UK). The detection antibody is in turn bound by an anti-species HRP-conjugated antibody and the signal is developed using a chromogenic substrate. Each stage is sequential and bound and free reagents are separated by

washing. The assay may also be performed using an anti-histone mark antibody to capture nucleosomes (and free histones) on to the solid phase, and an anti-nucleosome (or anti-DNA) antibody for detection.

5

A blocking reagent or treatment as described above may also be used, for example to deplete albumin or minimise interference from heterophilic antibodies.

10 In some embodiments, the nucleosomes in patient samples may be concentrated may be concentrated as described above.

15 The assay using the anti-nucleosomal antibody as the capture antibody is described in more detail below:

A Nunc Maxisorp 96-well ELISA plate was coated overnight at 4°C with a purified mouse anti-nucleosome monoclonal antibody at a concentration of 2.5µg/ml in a 20 carbonate/bicarbonate buffer pH 9.5, 50µl/well added (125ng/well). The contents of the plate were flicked out and washed three times with PBS (Dulbecco A). Blocking buffer (1% BSA in PBS + 0.05% Tween 20) was then added.

25 PPP derived from normal blood or buffer spiked with isolated chicken nucleosomes, or patient PPP samples were diluted appropriately with blocking buffer, and then by a further 5 dilutions giving a dilution range of 1/5 - 1/1215.

30

The block buffer was removed from the ELISA plate and diluted samples (for example 50µl) were transferred to the plate. Appropriate control wells were prepared.

The plate was sealed transferred to a shaking incubator (30°C) for a period of 2 hours. The plate was flicked out and washed 4 times with PBS.

- 5 Detection antibodies were appropriately diluted in block buffer and added to designated wells of the plate (typically 50µl/well). The plates were sealed and returned to the shaking incubator for a further 1.5 hours. The plates were washed as for the previous step, 10 followed by the addition of, for example, 50µl of the anti-rabbit HRP conjugate to all wells, then returned to the incubator for 1 hour.

The wash step was repeated on the plates and 100µl/well 15 of SureBlue TMB Microwell peroxidase substrate was added to all wells. The plates were returned to the shaker/incubator to allow development of the blue colour, typically for 40 minutes. Finally, the reaction was stopped by the addition of TMB Stop Solution. The plates 20 were read at a wavelength of 450nM.

Results

Spiking of normal blood with nucleosomes

- 25 Using the sandwich ELISA described above and an antibody to dimethylated lysine 4 of histone H3 as the second antibody, samples of buffer and normal blood both spiked with chicken nucleosomes generated equivalent signals (Fig.1). No significant signal was obtained from normal 30 blood that had not been spiked with chicken nucleosomes over the dilution range used in the assay(Fig.1).

Analysis of patient samples

Using the sandwich ELISA described above and antibodies to either an anti-histone H3 dimethyl lysine 4 antibody (Figure 2) or an anti-histone H3 acetyl lysine 9 antibody (Figure 3) as the second antibody in the ELISA, an increasing signal is measured as the concentration of the plasma sample increases.

10

15

Histone	Residue	Modification
H3	Arg 2	Me
H3	Arg 17	Me
H3	Arg 26	Me
H3	Lys 4	Me
H3	Lys 9	Me
H3	Lys 14	Me
H3	Lys 18	Me
H3	Lys 27	Me
H3	Lys 36	Me
H3	Lys 37	Me
H3	Lys 79	Me
H3	Lys 9	Ac
H3	Lys 14	Ac
H3	Lys 18	Ac
H3	Lys 23	Ac
H3	Lys 27	Ac
H3	Ser 10	Phos
H3	Ser 28	Phos
H3	Thr 11	Phos
H4	Arg 3	Me
H4	Lys 20	Me
H4	Lys 5	Ac
H4	Lys 8	Ac
H4	Lys 12	Ac
H4	Lys 16	Ac
H4	Lys 20	Ac
H4	Ser 1	Phos
H2A	Lys 5	Ac
H2A	Lys 9	Ac
H2A	Ser 1	Ac
H2A	Ser 1	Phos
H2A	Lys 119	Ubiq
H2B	Lys 5	Ac
H2B	Lys 12	Ac
H2B	Lys 15	Ac
H2B	Lys 20	Ac
H2B	Lys 24	Ac
H2B	Ser 14	Phos
H2B	Ser 32	Phos
H2B	Ser 36	Phos
H2B	Lys 120	Ubiq
H2A.X	Ser 1	Phos
H2A.X	Ser 139	Phos
H2A.X	Lys 119	Ubiq
H2A.X	Lys 5	Ac
H2A.X	Lys 9	Ac

H3.3	Arg 2	Me
H3.3	Arg 17	Me
H3.3	Arg 26	Me
H3.3	Lys 4	Me
H3.3	Lys 9	Me
H3.3	Lys 14	Me
H3.3	Lys 18	Me
H3.3	Lys 27	Me
H3.3	Lys 36	Me
H3.3	Lys 37	Me
H3.3	Lys 79	Me
H3.3	Lys 9	Ac
H3.3	Lys 14	Ac
H3.3	Lys 18	Ac
H3.3	Lys 23	Ac
H3.3	Lys 27	Ac
H3.3	Ser 10	Phos
H3.3	Ser 28	Phos
H3.3	Thr 11	Phos

Table 1

Histone	Residue	Modification
H3	Arg 2	Me
H3	Arg 17	Me
H3	Arg 26	Me
H3	Lys 14	Me
H3	Lys 18	Me
H3	Lys 37	Me
H3	Lys 79	Me
H3	Lys 9	Ac
H3	Lys 14	Ac
H3	Lys 18	Ac
H3	Lys 23	Ac
H3	Lys 27	Ac
H3	Ser 10	Phos
H3	Ser 28	Phos
H3	Thr 11	Phos
H4	Lys 8	Ac
H4	Lys 12	Ac
H4	Lys 16	Ac
H4	Lys 20	Ac
H4	Ser 1	Phos
H2A	Lys 5	Ac
H2A	Lys 9	Ac
H2A	Ser 1	Ac
H2A	Ser 1	Phos
H2A	Lys 119	Ubiq
H2B	Lys 5	Ac
H2B	Lys 12	Ac
H2B	Lys 15	Ac
H2B	Lys 20	Ac
H2B	Lys 24	Ac
H2B	Ser 32	Phos
H2B	Ser 36	Phos
H2B	Lys 120	Ubiq
H2A.X	Ser 1	Phos
H2A.X	Ser 139	Phos
H2A.X	Lys 119	Ubiq
H2A.X	Lys 5	Ac
H2A.X	Lys 9	Ac
H3.3	Arg 2	Me
H3.3	Arg 17	Me
H3.3	Arg 26	Me
H3.3	Lys 4	Me
H3.3	Lys 9	Me
H3.3	Lys 14	Me
H3.3	Lys 18	Me
H3.3	Lys 27	Me
H3.3	Lys 36	Me

H3.3	Lys 37	Me
H3.3	Lys 79	Me
H3.3	Lys 9	Ac
H3.3	Lys 14	Ac
H3.3	Lys 18	Ac
H3.3	Lys 23	Ac
H3.3	Lys 27	Ac
H3.3	Ser 10	Phos
H3.3	Ser 28	Phos
H3.3	Thr 11	Phos

Table 2

H3 lys 4 (Me) :	ARTK(M)QTAR (SEQ ID NO: 1)
H4 arg 3 (Me) :	SGR(M)GK (SEQ ID NO: 2)
H4 lys 5 (Ac) :	SGRGK(A) (SEQ ID NO: 3)
H3 lys 9 (Me) :	QTARK(M)STGV (SEQ ID NO: 6)
H2B ser 14 (Phos) :	SAPAPKKGS(P)KK (SEQ ID NO: 7)
H3 lys 27 (Me) :	AARK(M)SAPV <u>CG</u> (SEQ ID NO: 8)
H3 lys 36 (Me) :	SGGVK(M)KPH <u>KCG</u> (SEQ ID NO: 9)
H4 lys 20 (Me) :	RHRK(M)ILR <u>DCG</u> (SEQ ID NO: 10)
H4 arg3(Me)/lys 5(Ac) :	SGR(M)GK(A) (SEQ ID NO: 4)
H4 Ser 2 (phos)/Arg 3(me)/Lys 5 (Ac) :	S(P)GR(M)GK(A) (SEQ ID NO: 5)

Table 3

Claims:

5 1. A method of assessing a disease condition in an individual comprising;

contacting said nucleosomes from a biological fluid sample obtained from the individual with an antibody which binds specifically with a modified histone protein,

10 wherein binding of said antibody to said nucleosomes is indicative that the individual has a disease condition.

2. A method according to claim 1 wherein said 15 nucleosomes are concentrated from the biological fluid sample.

3. A method according to claim 1 or claim 2 wherein the 20 disease condition is a cancer condition or an autoimmune disease.

4. A method according to any one of the preceding claims wherein the modified histone has a modification shown in Table 1.

25 5. A method according to any one of the preceding claims wherein the modified histone has a modification shown in Table 2.

30 6. A method according to any one of the preceding claims wherein said antibody comprises a detectable label.

7. A method of assessing histone modification in nucleosomes in a biological fluid sample from an individual comprising;
 - contacting a biological fluid sample from said individual with a first antibody,
 - determining binding of said first antibody to a nucleosome containing a histone modification using a second antibody,
 - wherein one of said first or second antibodies binds to a nucleosome and the other of said first or second antibodies binds specifically to a modified histone.
8. A method according to claim 7 wherein said first antibody binds to nucleosomes and the second antibody binds specifically to the modified histone
9. A method according to claim 7 wherein the second antibody binds to nucleosomes and the first antibody binds specifically to the modified histone.
10. A method according to any one of claims 7 to 9 wherein the modified histone comprises a modification shown in Table 1.
11. A method according to any one of claims 7 to 9 wherein the modified histone comprises a modification shown in Table 2.
12. A method wherein according to any one of claims 7 to 11 the biological fluid sample is a plasma or serum sample.

13. A method according to any one of claims 7 to 12 wherein said first or said second antibody is immobilised.

5 14. A method according to claim 13 wherein the non-immobilised antibody of said first and second antibodies comprises a detectable label.

10 15. A method of assessing histone modification in cell-free nucleosomes in a biological fluid sample comprising; contacting a biological fluid sample with an antibody which binds specifically to a histone comprising a modification, determining the binding of said antibody to nucleosomes in said sample, the binding of said antibody being indicative of the presence of modified histone in nucleosomes in the blood of said individual.

20 16. A method according to claim 15 wherein the modification is a modification shown in Table 1.

17. A method according to claim 15 or claim 16 wherein the modification is a modification shown in Table 2.

25 18. A method according to any one of claims 15 to 17 wherein the disease condition is a cancer condition or an autoimmune disease.

30 19. A method according to any one of claims 15 to 18 wherein said antibody comprises a detectable label.

20. A method of diagnosing a cancer condition in an individual comprising;

contacting biological fluid sample obtained from an individual with an antibody which binds specifically to a modified histone,

5 determining the binding of said antibody to nucleosomes in said sample,

the binding of said antibody to nucleosomes in said sample being indicative that said individual has a cancer condition.

10 21. A method according to claim 20 wherein the disease condition is a cancer condition or an autoimmune disease.

22. A method according to claim 20 or claim 21 wherein the modified histone has a modification shown in Table 1.

15 23. A method according to any one of claims 20 to 22 wherein the modified histone has a modification shown in Table 2

20 24. A method according to any one of claims 20 to 23 wherein said modification is not H2B Ser 14 (P).

25 25. A method according to any one of claims 20 to 24 wherein said antibody comprises a detectable label.

26. A method according to any one of claims 1 to 25 comprising isolating DNA associated with the nucleosome comprising a modified histone.

30 27. A method according to claim 26 comprising amplifying said nucleosome associated DNA.

28. A method according to claim 26 or claim 27 comprising sequencing said nucleosome associated DNA.

29. A method according to any one of claims 26 to 28 comprising labelling said nucleosome associated DNA with a detectable label.

5

30. A method according to any one of claims 26 to 29 comprising contacting said nucleosome associated DNA with a DNA molecule having a known sequence under conditions suitable for hybridisation and determining hybridisation.

10

31. A method according to claim 30 wherein said DNA molecule of known sequence is comprised in a microarray.

32. A method according to any one of claims 26 to 31
15 claim comprising determining the hybridisation of DNA from said individual which is associated with said histone modification relative to DNA associated with said histone modification from one or more other individuals.

20

33. A method according to any one of claims 26 to 31 wherein said modified histone comprises a modification associated with gene silencing.

34. A method according to claim 33 wherein said modification is selected from H3 Lys 9 (Me), H3 Lys 27(Me), H3 Lys 36(Me), H3 Lys 79(Me) and H4 Lys 20(Me).

35. A method according to any one of claims 26 to 34 wherein said modified histone comprises a modification
30 associated with gene activation.

36. A method according to claim 35 wherein said modification is selected from H3 Lys 4 (Me), H3 Lys 9(Ac), H3 Lys 14(Ac) and H3 Lys 23(Ac).

37. A method of identifying a tumour suppressor gene comprising;

5 contacting biological fluid sample obtained from an individual suffering from a cancer condition with an antibody which binds specifically to a histone having a modification associated with silencing,

10 isolating nucleosomes bound to said antibody, sequencing DNA associated with said bound nucleosomes, and;

15 identifying said DNA as a tumor suppressor gene.

38. A method according to claim 37 wherein said modification is selected from H3 Lys 9 (Me) H3 Lys 27(Me), H3 Lys 36(Me), H3 Lys 79(Me) and H4 Lys 20(Me).

39. A method of identifying an oncogene comprising;

20 contacting biological fluid sample obtained from an individual suffering from a cancer condition with an antibody which binds specifically to a histone having a modification associated with activation,

25 isolating nucleosomes bound to said antibody, sequencing DNA associated with said bound nucleosomes, and;

30 identifying said DNA as an oncogene.

40. A method according to claim 39 wherein said modified histone comprises a modification shown in Table 1 and/or Table 2.

30

41. A method of identifying a patient as a responsive to histone modification modulation therapy comprising;

determining the level of histone modification in cell-free nucleosomes within a sample obtained from the

patient, relative to a sample obtained from a healthy individual,

5 a change in the level of modification being indicative that the patient is responsive to histone modification modulation therapy.

42. A method of assessing a patient for a therapeutic treatment comprising;

10 determining the presence of one or more genes which confer resistance to said treatment in cell-free nucleosomes in a sample obtained from the patient, wherein said nucleosomes comprise a histone modification associated with activation.

15 43. A method according to claim 42 wherein said modification is a modification shown in Table 1 and/or Table 2.

20 44. A method of determining the presence of a cell-free nucleosome having a histone modification comprising;

determining the presence of an antibody which binds specifically to the histone modification in a sample obtained from an individual,


25 the presence of said antibody being indicative of the presence of said nucleosomes in said individual.

45. A method according to claim 44 comprising contacting the sample with an antigen comprising a histone modification epitope and determining binding to the 30 antigen.

46. A method according to claim 45 wherein said antigen is immobilised on a solid support.

47. A method according to claim 45 wherein said antigen comprises a detectable label.

48. A method according to any one of claims 44 to 47
5 wherein said modified histone comprises a modification shown in Table 1 and/or Table 2.



Dilution of spiked blood/buffer




Figure 2




Figure 3

PCT/GB2004/003564

